Fortress Biotech Inc

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

FBIO$1.99+7.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets


· · December 31,
· · 2023 · · 2022
· · · ·
ASSETS · ·
Current assets · ·
Cash and cash equivalents	$80,927	$178,266
Accounts receivable, net	15,222	28,208
Inventory	10,206	14,159
Other receivables - related party	167	138
Prepaid expenses and other current assets	10,500	9,661
Total current assets	117,022	230,432

Property, plant and equipment, net	6,505	13,020
Operating lease right-of-use asset, net	16,990	19,991
Restricted cash	2,438	2,688
Intangible asset, net	20,287	27,197
Other assets	4,284	973
Total assets	$167,526	$294,301

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities
Accounts payable and accrued expenses	$73,562	$97,446
Income taxes payable	843	722
Common stock warrant liabilities	886	13,869
Operating lease liabilities, short-term	2,523	2,447
Partner company convertible preferred shares, short-term, net	3,931	2,052
Partner company line of credit	—	2,948
Partner company installment payments - licenses, short-term, net	3,000	7,235
Other short-term liabilities	163	996
Total current liabilities	84,908	127,715

Notes payable, long-term, net	60,856	91,730
Operating lease liabilities, long-term	18,282	21,572
Partner company installment payments - licenses, long-term, net	—	1,412
Other long-term liabilities	1,893	1,847
Total liabilities	165,939	244,276

Commitments and contingencies (Note 14)

Stockholders’ equity (deficit)
Cumulative redeemable perpetual preferred stock, $0.001 par value, 15,000,000 authorized, 5,000,000 designated Series A shares, 3,427,138 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively, liquidation value of $25.00 per share	3	3
Common stock, $0.001 par value, 200,000,000 shares authorized, 15,093,053 and 7,366,283 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	15	7
Additional paid-in-capital	717,396	675,944
Accumulated deficit	(694,870)	(634,233)
Total stockholders' equity attributed to the Company	22,544	41,721

Non-controlling interests	(20,957)	8,304
Total stockholders' equity (deficit)	1,587	50,025
Total liabilities and stockholders' equity (deficit)	$167,526	$294,301

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.